Connective tissue diseases: Lupus nephritis - Winning a few battles but not the war

Nature Reviews Rheumatology

Volumn 7, Issue 8, 2011, Pages 441-442

  Bertsias, George K ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CYCLOPHOSPHAMIDE;

AFRICAN AMERICAN; CONNECTIVE TISSUE DISEASE; DIABETES MELLITUS; ETHNICITY; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

HEALTH PLANNING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; PROGNOSIS; SURVIVAL RATE;

EID: 80051471030     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.88     Document Type: Short Survey

References (10)

1. Costenbader, K. H. et al. Trends in the incidence, demographics and outcomes of end-stage renal disease due to lupus nephritis in the U. S., 1995-2006. Arthritis Rheum. 63, 1681-1688 (2011).
2. Hiraki, L. T. et al. End-stage renal disease due to lupus nephritis among children in the U. S., 1995-2006. Arthritis Rheum. doi:10.1002/art.30350.
3. Ward, M. M. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch. Intern. Med. 160, 3136-3140 (2000).
4. Boumpas, D. T., Bertsias, G. K. & Balow, J. E. A decade of mycophenolate mofetil for lupus nephritis: Is the glass half-empty or half-full? Ann. Rheum. Dis. 69, 2059-2061 (2010).
5. Ward, M. M. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J. Rheumatol. 36, 63-67 (2009).
6. Winkelmayer, W. C. Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. Semin. Dial. 23, 486-491 (2010).
7. Houssiau, F. A. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 69, 61-64 (2010).
8. Bertsias, G. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 67, 195-205 (2008). (Pubitemid 351183308)
9. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103-1112 (2009).
10. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).